Abstract: The hybrid measurement system includes an evanescent prism coupling spectroscopy (EPCS) sub-system and a light-scattering polarimetry (LSP) sub-system. The EPCS sub-system includes an EPCS light source optically coupled to an EPCS detector system through an EPCS coupling prism. The LSP sub-system includes an LSP light source optically coupled to an optical compensator, which in turn is optically coupled to a LSP detector system via a LSP coupling prism. A support structure supports the EPCS and LSP coupling prisms to define a coupling prism assembly, which supports the two prisms at a measurement location. Stress measurements made using the EPCS and LSP sub-systems are combined to fully characterize the stress properties of a transparent chemically strengthened substrate. Methods of processing the EPCS and LSP measurements to improve measurement accuracy are also disclosed.

Abstract: Systems and methods for interactive site resource management are disclosed. In certain embodiments, the system and method collects and accesses local geospatially-referenced landscape and site survey data in the field as facilitated by selectable content views, the gathered landscape and site survey data synthesized with baseline geospatially-referenced landscape and site survey data. In one aspect, the synthesized landscape and site geospatially-referenced survey data may be used by a project lead or authority agent, to create a landscape and/or site report, an authorized development plan, a master landscape and/or site survey, and/or as-built development plans. In certain embodiments, the synthesized landscape site survey data is presented as an augmented reality display.

Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.

Abstract: Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.

Abstract: A dispensing package comprising one or more jackets, a screw assembly, and a movable elevator platform; the screw assembly comprising a spindle comprising two external thread portions, which allows for a quick first turn.

Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolodin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.

Abstract: A system includes least one processor in communication with a memory storing instructions, the at least one processor to receive an authentication request comprising authentication information from a user requesting access to a computing device connected to a communications network, determine a type of authentication request sent by the user, transmit the authentication request to an appropriate authentication server responsive to the type of authentication request, receive an authentication response from the appropriate authentication server, determine a permission level for the user requesting access to the computing device and attach the permission level to the authentication response, and transmit the authentication response to the user requesting access to the computing device.

Abstract: Systems, methods, and devices for generating an image frame for display to a user. Brain activity sensor data correlated with movement of a user is received. A predicted field of view of the user is determined based on the brain activity sensor data. An image frame is generated based on the predicted field of view. The image frame is transmitted to a display for display to a user. Some implementations provide for receiving and displaying a foveated image frame based on a predicted field of view of a user. Brain activity information of a user is captured. The brain activity information is communicated to a transceiver. The brain activity information is transmitted to a rendering device using the transceiver to generate a foveated image frame based on a predicted field of view of the user. The foveated image frame is received from the rendering device, decoded, and displayed to the user.

Abstract: This invention is based on the discovery that many lung diseases associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The severity of age-related conditions typically correlates with the abundance of senescent cells: thus, clearing senescent cells can help abrogate the condition: providing symptomatic relief, and potentially inhibiting disease progression. In accordance with this invention, a family of Bcl protein inhibitors has been developed for the treatment of lung diseases. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable pulmonary diseases.

Abstract: A dispensing package comprising one or more jackets, a screw assembly, and a movable elevator platform; the screw assembly comprising a spindle comprising two external thread portions, which allows for a quick first turn.

Abstract: Systems, methods, and devices for generating an image frame for display to a user. Brain activity sensor data correlated with movement of a user is received. A predicted field of view of the user is determined based on the brain activity sensor data. An image frame is generated based on the predicted field of view. The image frame is transmitted to a display for display to a user. Some implementations provide for receiving and displaying a foveated image frame based on a predicted field of view of a user. Brain activity information of a user is captured. The brain activity information is communicated to a transceiver. The brain activity information is transmitted to a rendering device using the transceiver to generate a foveated image frame based on a predicted field of view of the user. The foveated image frame is received from the rendering device, decoded, and displayed to the user.

Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.

Abstract: Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

Abstract: Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: A laminate structure is provided that allows the surface renewal and rework of a device by the selective removal of layers of the laminate. The selective removal may be achieved by heating or irradiating the laminate structure, such that an adhesive layer debonds and allows the removal of a damaged layer to provide a pristine surface.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: A transport device comprising a battery pack and a chassis member at least partially encased in the battery pack.